Calcionics Appoints Daniel O. Wilds Executive Chairman
Mr. Wilds recently retired as CEO of SCOLR Pharma, Inc. He previously served as Chairman and CEO at Northwest Biotherapeutics, Inc., as CEO at Shiloov Biotechnologies (USA), as CEO of Adeza BioMedical, and as CEO of Medisense, Inc. Mr. Wilds started his career at Baxter International in 1968 where he held various domestic and international senior management positions for more than 20 years including being president of Baxter’s chemotherapy service business and of Travenol-Genentech, a joint venture between Baxter and Genentech. He currently serves on the board of directors of Helix BioMedix, Inc.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.